GENEVA, Switzerland--(BUSINESS WIRE)--July 31, 2006--Acrongenomics, Inc. (OTCBB:AGNM - News) and Molecular Vision, Ltd. -- an Imperial Innovations spin-out company -- today present an R&D update of their joint collaboration, following the meeting of the project's steering committee, that took place on 28th July 2006 at Molecular Vision's site in London. The two companies envisage accelerating the development and commercialization of low-cost, easy-to-use and readily portable Point-of-Care (POC) diagnostic devices. Initial devices will enable personalized on-the-spot monitoring for diabetes management and diagnosis of STDs (Sexually Transmitted Diseases), cardiovascular diseases and substances of abuse, based on the unique BioLED technology platform.
